Trial Profile

Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Rilpivirine; Tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Pharmacokinetics; Registrational
Sponsors Gilead Sciences

Most Recent Events

24 Nov 2010 This bioequivalence study conducted by Gilead provides support for the Gilead NDA submitted to the US FDA for emtricitabine/rilpivirine/tenofovir disoproxil fumarate [Truvada/TMC278], according to a Gilead Sciences media release.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com